SEC Filings
State Street Holds 9 Million CytomX Shares Without Seeking To Influence Control
The passive holding represents 4.1% of the common-stock class as CytomX prepares an approval-supporting cancer study.
CytomX Therapeutics (CTMX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The passive holding represents 4.1% of the common-stock class as CytomX prepares an approval-supporting cancer study.
SEC Filings
The drug developer expects funding to last into the second half of 2028, with a colorectal-cancer trial update due in January 2027.
Earnings
Varsetta-M's next update will include overall survival, which management expects to be the main goal of its first registrational study.